Much of the antagonistic ER response to tamoxifen is mediated by NCoR1 [6]; and reduced NCoR1 expression in ER-positive primary breast cancers predicts for tamoxifen resistance and early metastatic relapse [7]. This evidence concerns the gene ESR1 and breast cancer.